ライフサイエンスコーパス: conjugated equine estrogen

1 Studies have shown that conjugated equine estrogen 0.625 mg a day plus medroxypr

2 me inhibitors [3]) were randomly assigned to conjugated equine estrogens 0.625 mg (combined with medr

3 ized, single-blind, crossover treatment with conjugated equine estrogens 0.625 mg per os per day, ram

4 usal women randomized to treatment with oral conjugated equine estrogen (0.625 mg/d), estrogen plus p

5 Women with prior hysterectomy received oral conjugated equine estrogen (0.625 mg/day) or placebo.

6 dy of the Women's Health Initiative trial of conjugated equine estrogens (0.625 mg per day) as compar

7 s were randomly assigned to a combination of conjugated equine estrogens (0.625 mg per day) plus medr

8 rticipants were randomly assigned to receive conjugated equine estrogens (0.625 mg per day) plus medr

9 ct uterus (n=2763) were randomly assigned to conjugated equine estrogens (0.625 mg) combined with med

10 6,608 women with a uterus were randomized to conjugated equine estrogens (0.625 mg/d [estrogen]) plus

11 andomized postmenopausal women to placebo or conjugated equine estrogens (0.625 mg/d) plus medroxypro

12 Continuous therapy with conjugated equine estrogen, 0.3 mg/d, and medroxyprogest

13 ltibotanical plus dietary soy counseling; 4) conjugated equine estrogen, 0.625 mg daily, with or with

14 oxifene, 60 mg/d; raloxifene, 120 mg/d; HRT (conjugated equine estrogen, 0.625 mg/d, and medroxyproge

15 Women were randomly assigned to receive conjugated equine estrogen, 0.625 mg/d, plus medroxyprog

16 orial design to receive hormone replacement (conjugated equine estrogen, 0.625 mg/d, with or without

17 Conjugated equine estrogens, 0.625 mg, plus medroxyproge

18 Conjugated equine estrogens, 0.625 mg, plus medroxyproge

19 nts were randomly assigned to receive either conjugated equine estrogens, 0.625 mg, plus medroxyproge

20 Conjugated equine estrogens, 0.625 mg/d, plus medroxypro

21 s were randomly assigned to receive combined conjugated equine estrogens, 0.625 mg/d, plus medroxypro

22 Participants received conjugated equine estrogens, 0.625 mg/d, plus medroxypro

23 Annual smears; oral conjugated equine estrogens, 0.625 mg/d, plus medroxypro

24 Twenty-one-day treatment with conjugated equine estrogens, 1.25 mg/d, randomly crossed

25 n with prior hysterectomy were randomized to conjugated equine estrogens alone (0.625 mg/d) or placeb

26 ing statistical significance in the trial of conjugated equine estrogens alone in women with prior hy

27 cases over a mean of 7.1 years among 10 251 conjugated equine estrogens alone participants.

28 Conjugated equine estrogen and 17beta-estradiol have con

29 d 1 daily tablet containing 0.625 mg of oral conjugated equine estrogen and 2.5 mg of medroxyprogeste

30 ed coronary heart disease who received daily conjugated equine estrogen and medroxy-progesterone acet

31 Continuous low-dose HRT with conjugated equine estrogen and oral medroxyprogesterone

32 Hormone therapy with conjugated equine estrogen and progestin had no signific

33 rmone replacement (oral dose of 0.625 mg/day conjugated equine estrogens and 2.5 mg/day medroxyproges

34 for 30 months; 25 received 175 microg/day of conjugated equine estrogens, and 21 served as untreated

35 Among these women, use of conjugated equine estrogens appeared to produce elevatio

36 rgone oophorectomy and hysterectomy received conjugated equine estrogens (at least 0.625 mg per day o

37 Our finding that conjugated equine estrogen but not esterified estrogen w

38 We randomly assigned 28 women to conjugated equine estrogen (CE) 0.625 mg, simvastatin 10

39 assigned 28 healthy postmenopausal women to conjugated equine estrogens (CE) 0.625 mg/d, vitamin E 8

40 r random assignment to hormone therapy (HT) (conjugated equine estrogen (CEE) alone or CEE plus medro

41 mly assigned to receive either 0.625 mg/d of conjugated equine estrogen (CEE) or placebo.

42 ught to test whether one month of daily oral conjugated equine estrogen (CEE) or transdermal estradio

43 The 3 ERT regimes studied were: (1) oral conjugated equine estrogen (CEE), (2) oral 17-beta estra

44 tmenopausal women with prior hysterectomy to conjugated equine estrogen (CEE; 0.625 mg/d) or placebo.

45 men aged 50 to 79 years who were given daily conjugated equine estrogen (CEE; 0.625 mg; n=5310) or pl

46 tigated associations between the use of oral conjugated equine estrogens (CEE) (0.625 mg/day) plus me

47 ind, placebo-controlled, randomized trial of conjugated equine estrogens (CEE) 0.625 mg daily plus me

48 Trial who were randomly assigned to receive conjugated equine estrogens (CEE) 0.625 mg/d; CEE and me

49 undergone a hysterectomy were randomized to conjugated equine estrogens (CEE) or placebo and 16,608

50 itive impairment (MCI) in women treated with conjugated equine estrogens (CEE) plus medroxyprogestero

51 lth Initiative Estrogen-Aone trial comparing conjugated equine estrogens (CEE) with placebo was stopp

52 Treatments were placebo, conjugated equine estrogens (CEE), CEE plus cyclic medro

53 Conjugated equine estrogens (CEE, 0.625 mg/d) plus medro

54 Women with an intact uterus received conjugated equine estrogens (CEE; 0.625 mg/d) plus medro

55 However, the effects of conjugated equine estrogens (CEEs) alone on mammographic

56 risk among women assigned to daily 0.625-mg conjugated equine estrogens (CEEs) compared with placebo

57 Lower-than-commonly-prescribed doses of conjugated equine estrogens (CEEs) with medroxyprogester

58 of this study was to compare the effects of conjugated equine estrogens (CEEs) with those of tamoxif

59 stricted to estrogen users, current users of conjugated equine estrogen had a higher risk than curren

60 In contrast, women currently taking conjugated equine estrogen had an elevated risk (OR, 1.6

61 Health Initiative, indicating that unopposed conjugated equine estrogen is unlikely to be cardioprote

62 BF measurements were repeated after 25 mg of conjugated equine estrogens IV.

63 findings from these trials, which used oral conjugated equine estrogens, may not be generalizable to

64 re randomly assigned to receive 0.625 mg/day conjugated equine estrogens (n = 5,076), or placebo (n =

65 randomized to receive 4 y of 0.45 mg/d oral conjugated equine estrogens (o-CEE) plus 200 mg/d micron

66 Oral conjugated equine estrogens (o-CEE), 0.45 mg/d, or trans

67 mg/d) if they had a uterus (N=16 608) or to conjugated equine estrogens only if they had prior hyste

68 sturbances were randomly assigned to receive conjugated equine estrogens or placebo in a 4-week clini

69 eceived either 1 daily tablet of 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogest

70 line to estrogen plus progestin (0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogest

71 Random assignment to 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyproge

72 Participants received 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyproge

73 mly assigned to receive either 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyproge

74 Conjugated equine estrogen plus medroxyprogesterone acet

75 follow-up of 4.1 years, treatment with oral conjugated equine estrogen plus medroxyprogesterone acet

76 n which one study group received 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyproges

77 One tablet per day containing 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyproges

78 Either 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyproges

79 progestin (n = 8,240), given as 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyproge

80 f invasive breast cancer with daily 0.625-mg conjugated equine estrogens plus 2.5-mg medroxyprogester

81 and Estrogen/Progestin Replacement Study) of conjugated equine estrogens plus medroxyprogesterone fai

82 orial design to receive either 0.625 mg/d of conjugated equine estrogen (plus 2.5 mg/d of medroxyprog

83 monkeys were ovariectomized and treated with conjugated equine estrogens (Premarin) at doses that are

84 en with coronary disease and hyperlipidemia, conjugated equine estrogen produced significant improvem

85 r 3 years, the first group received ERT with conjugated equine estrogens, the second group received S

86 The active regimens were conjugated equine estrogens therapy at 0.625 mg daily, a

87 Among conjugated equine estrogen users, increasing daily dose

88 either 1 daily tablet containing 0.625 mg of conjugated equine estrogen with 2.5 mg of medroxyprogest

89 nopausal women with coronary artery disease, conjugated equine estrogen with or without continuous ad

90 in relation to current use of esterified or conjugated equine estrogens, with or without concomitant

91 Initiative randomized trials (1993-2004) of conjugated equine estrogens, with or without medroxyprog